Author: [email protected]

Energy Fuels Makes a $1.9 Billion Bet to Build a Western Rare Earth Supply Chain From Mine to Magnet

Posted on by [email protected]

In one of the most strategically significant critical minerals deals of the year, Energy Fuels (NYSE American: UUUU) (TSX: EFR) announced Tuesday it has entered into a definitive agreement to acquire Vacuumschmelze GmbH & Co. KG and its affiliated entities — collectively known as VAC — from private equity firm Ara Partners in a cash-and-stock transaction valued at approximately $1.9 billion. The deal is designed to create a fully integrated rare earth supply chain spanning everything from mining through finished permanent magnet manufacturing, reducing Western dependence on China for materials that are essential to defense, automotive, robotics, and data center applications.

The transaction values VAC at $1.9 billion based on Energy Fuels’ closing share price of $16.12 on June 22, and is structured as $718 million in cash plus 65.853 million newly issued Energy Fuels shares. Energy Fuels will also assume approximately $140 million of VAC’s adjusted net debt. Energy Fuels shares slipped roughly 2% in premarket trading following the announcement, a common reaction when an acquirer issues significant new equity to fund a large deal.

What Energy Fuels Is Acquiring

VAC is not an early-stage company. Headquartered in Hanau, Germany, the business brings more than 100 years of advanced magnetics expertise, over 400 patents, more than 1,000 customers, and manufacturing operations across North America, Europe, and Asia. Its most strategically important asset is a recently commissioned permanent magnet facility in Sumter, South Carolina, which currently has capacity for 2,000 tonnes per year of rare earth permanent magnets and is scalable to 12,000 tonnes per year.

Permanent magnets are the critical end product in the rare earth value chain. They are essential components in electric vehicle motors, wind turbines, defense systems, robotics, and the cooling and power infrastructure inside AI data centers. The overwhelming majority of global permanent magnet production currently takes place in China, which has made supply chain security in this category a top priority for the United States and its allies.

The Mine-to-Magnet Strategy

The strategic logic behind the deal is vertical integration across the entire rare earth value chain. Energy Fuels brings the upstream capabilities — mining, processing, and refining — anchored by its White Mesa Mill in Utah, the only conventional uranium and rare earth processing facility of its kind in the United States. VAC contributes the downstream capabilities of metals and alloy production and finished magnet manufacturing.

Combining the two creates what the company describes as a fully integrated mine-to-magnet platform. Under the plan, rare earth oxides produced at the White Mesa Mill would be converted into metals and alloys at facilities in Korea and the United States, then manufactured into finished permanent magnets at VAC’s Sumter facility and its European operations. The Sumter site is also expected to be fed by rare earth oxides from Energy Fuels’ Donald Project in Australia, which is anticipated to reach a final investment decision in the third quarter of 2026 and be commissioned in 2028.

The Government Backing

The deal does not stand alone. Just last week, Energy Fuels announced it had received conditional US government support to accelerate its growth in rare earths and critical materials, including a $725 million conditional loan from the US Office of Strategic Capital. That federal backing reflects the strategic priority Washington has placed on building domestic and allied critical minerals supply chains, a theme that has run through multiple government interventions in 2026 including stakes in quantum computing companies and rare earth miners.

For investors tracking the critical minerals and rare earth space, the Energy Fuels-VAC combination represents one of the clearest examples yet of a smaller company moving aggressively to build a fully integrated, government-supported alternative to Chinese supply chain dominance. As demand for permanent magnets accelerates across defense, electric vehicles, robotics, and AI infrastructure, control of the full value chain from mine to finished magnet is becoming one of the most strategically valuable positions in the entire materials sector.

Eledon Pharmaceuticals (ELDN) – Eledon Presents Data Update From Phase 2 Trial With Clinical Trial Plans

Posted on by [email protected]


Tuesday, June 23, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Long-Term Outcomes Favor Tegoprubart. Eledon presented long-term data from its Phase 2 BESTOW trial at the American Transplantation Congress (ATC). The BESTOW trial tested tegoprubart as part of the immunosuppressive regimen for patients receiving kidney transplants. Data from the Open Label Extension study showed consistent improvements in kidney function and a reduction in rejection episodes. Importantly, the side effect profile continues to show significant  improvements over tacrolimus, the standard of care.

Trial Background. The Phase 2 BESTOW trial was a double-blind study testing tegoprubart as an immunosuppressive after kidney transplantation. An active comparator arm included tacrolimus as an immunosuppressive. The primary endpoint of the trial was eGFR (estimated Glomerular Filtration Rate) and BPAR (Biopsy Proven Acute Rejection) episodes. Following the completion of the 12-month course of treatment, patients were given the option to continue in an Open Label Extension (OLE) study.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Boundless Bio Pivots From Cancer to a Rare Genetic Disease in a Reverse Merger With Serapha Bio

Posted on by [email protected]

In a transaction that illustrates how struggling clinical-stage biotechs are increasingly being repurposed as vehicles for more promising assets, Boundless Bio (Nasdaq: BOLD) announced Tuesday it has entered into a definitive all-stock merger agreement with privately held Serapha Bio. The deal will see Serapha combine with Boundless Bio and effectively take over the public company, pivoting the combined entity away from Boundless’s cancer research and toward Serapha’s gene editing therapy for a serious inherited disease. Boundless Bio shares surged approximately 75% on the news to around $2.50.

Upon completion, the combined company will operate under the name Serapha Bio and is expected to trade on Nasdaq under the new ticker symbol “AATD” — a direct reference to the disease its lead program targets.

The Structure of the Deal

This is a reverse merger, a structure in which a private company merges into a public one to gain a stock market listing without conducting a traditional IPO. The ownership split makes the dynamic clear: pre-merger Boundless Bio stockholders are expected to own approximately 3.7% of the combined company, while pre-merger Serapha stockholders — including investors participating in the concurrent financing — will own approximately 96.3%.

Two features make this transaction particularly notable for shareholders. First, alongside the merger, Serapha is raising $230 million in a concurrent private placement co-led by RTW Investments and RA Capital Management, with participation from a syndicate of top healthcare investors and mutual funds. That level of institutional backing provides the combined company with substantial capital to advance its lead program through clinical development. Second, prior to closing, Boundless Bio expects to declare a cash dividend to its pre-merger stockholders to distribute excess net cash, currently estimated at approximately $44 million to $48 million. That dividend, combined with the stock’s jump, gives existing Boundless holders both an immediate cash return and continued exposure to the new program.

What Serapha Is Actually Developing

Serapha’s lead program, SERP-01, is an investigational in vivo base editing therapy targeting Alpha-1 Antitrypsin Deficiency, a serious inherited genetic disorder that can cause progressive lung and liver disease. The therapy specifically targets the SERPINA1 E342K mutation — known as the PiZZ genotype — which is the most common cause of severe AATD. The company has reported proof-of-concept data demonstrating restoration of serum AAT to normal levels, an encouraging early signal for a disease that currently has limited treatment options.

The asset has an international development backstory. Serapha licensed SERP-01, developed as YOLT-202 in Greater China, from YolTech Therapeutics in June 2026 in exchange for an upfront cash payment and a minority equity stake. Under the agreement, YolTech is eligible to receive regulatory and commercial milestones totaling over $2 billion plus tiered royalties, while retaining development and commercialization rights for the Greater China territory. YolTech has been enrolling AATD patients in an investigator-initiated trial at Renji Hospital in Shanghai.

The Small Cap Biotech Read

For investors tracking the small and microcap biotech space, this transaction reflects a pattern that has become increasingly common in 2026. Clinical-stage companies whose original programs have stalled or been deprioritized are valuable to private biotechs precisely because of what they already possess: a Nasdaq listing, a cash balance, and an existing shareholder base. Rather than navigate the lengthy and uncertain IPO process, a promising private company like Serapha can access public markets, raise institutional capital, and advance its lead asset all in a single coordinated transaction.

The base editing space in particular has attracted significant investor attention as next-generation gene editing technologies move from theoretical promise toward clinical proof of concept. With $230 million in fresh capital, validated early data, and a clear regulatory target in a serious genetic disease, the newly formed Serapha Bio enters the public market positioned to advance one of the more closely watched programs in the in vivo base editing field. The transaction is expected to close in the fourth quarter of 2026, subject to stockholder approval and customary closing conditions.

Markets Reopen Into a Week That Could Decide Whether the Fed Hikes in 2026

Posted on by [email protected]

US markets returned Monday from the Juneteenth holiday weekend and walked straight into one of the most consequential data weeks of the year. After Federal Reserve Chair Kevin Warsh’s hawkish debut last Wednesday — which saw the central bank hold rates while signaling that nine of 18 officials now project at least one rate hike before year-end — the coming days will deliver the economic readings that determine whether that hike moves from projection to reality. For small and microcap investors, this is the week the second half of 2026 takes shape.

The May PCE Reading Is the Number That Matters

The single most important data point this week arrives Friday with the release of the May Personal Consumption Expenditures price index — the Fed’s preferred inflation gauge. While the Consumer Price Index gets more headlines, PCE is the measure the FOMC actually uses to assess progress toward its 2% target, which makes Friday’s print the most direct evidence yet of whether inflation is cooling or entrenching.

The context heightens the stakes. May CPI came in at 4.2% year over year, the highest in three years, driven heavily by energy costs tied to the now-easing US-Iran conflict. If PCE confirms that inflation pressure, it strengthens the case for the rate hike the dot plot is signaling. If it shows the energy spike was the dominant and possibly peaking driver — with core inflation more contained — it gives the Fed room to hold without tightening further. Either outcome moves Treasury yields, and Treasury yields move small caps.

GDP Revisions Add Another Layer

Before Friday’s inflation data, markets will digest revised first-quarter GDP figures. The revision matters because it recalibrates the growth side of the Fed’s dual mandate. A stronger-than-expected economy gives the committee more justification to tighten without fear of triggering a downturn. A softer reading complicates the hawkish case and raises the specter of stagflation — weak growth paired with stubborn inflation — which is the single most difficult environment for the Fed to navigate and historically the hardest for smaller, rate-sensitive companies to weather.

Earnings Worth Watching

On the corporate side, two bellwether reports land this week. Micron reports quarterly results that will serve as a direct read on AI-driven memory demand, building on the supercycle narrative that has lifted the entire semiconductor space this year. After Broadcom’s recent guidance-driven selloff reset expectations across chip names, Micron’s numbers will test whether the underlying demand story remains intact for the smaller semiconductor and component companies operating downstream of the same AI buildout.

FedEx also reports, and its results function as a broad economic barometer. As a global logistics operator, FedEx’s volume data and forward guidance offer a real-time read on shipping activity, consumer demand, and industrial output — all directly relevant to the domestically focused small caps that make up the Russell 2000.

Why This Week Matters for Small Caps

Small and microcap companies carry disproportionately more variable-rate debt than their large cap counterparts, which means the rate path being shaped this week translates directly into their cost of capital and earnings trajectory. The Russell 2000 has spent 2026 caught between strong underlying fundamentals — historic valuation discounts, improving earnings growth, and domestic revenue exposure — and a punishing rate environment that has capped its performance relative to large caps.

This week’s data will tilt that balance. A benign PCE print and solid GDP would support the case that the Fed can hold rather than hike, removing an overhang that has weighed on smaller companies all year. A hot inflation reading paired with strong growth would validate the hawkish dot plot and extend the higher-for-longer environment further into the future. Either way, by Friday afte

Alan Greenspan, the Most Powerful Central Banker of His Era, Dies at 100

Posted on by [email protected]

Alan Greenspan, who chaired the Federal Reserve for more than 18 years across four presidential administrations and became the most recognizable central banker in modern history, died Monday at his home in Washington from complications of Parkinson’s disease. He was 100 years old. His death, confirmed by his wife of 29 years, NBC News correspondent Andrea Mitchell, closes the book on a figure whose words and decisions shaped American markets for nearly two decades and whose legacy continues to influence how investors and policymakers think about the role of the Fed today.

Few figures in financial history wielded the kind of market-moving power Greenspan commanded. From his appointment by President Reagan in 1987 through his retirement in 2006, his public remarks were parsed word by word by investors, economists, and lawmakers alike. The deliberate ambiguity of his communication style became so well known it earned its own name — “Fedspeak” — a dialect he later admitted he cultivated intentionally to avoid moving markets before the Fed was ready to act.

The Maestro Years

Greenspan presided over one of the longest economic expansions in US history, a boom stretching from 1991 to 2001, and his tenure coincided with the period economists came to call the “Great Moderation” — a stretch of low inflation, steady growth, and rising markets from the mid-1980s through 2007. He broke with central banking orthodoxy by allowing unemployment to fall to historically low levels without preemptively raising rates, a willingness to “watch and wait” that defined his data-driven approach and helped sustain the expansion of the 1990s.

His most enduring contribution to the financial lexicon came in 1996, when he warned of “irrational exuberance” in asset prices — a phrase that sent immediate shivers through global markets even though the dot-com bubble he alluded to would not burst for another five years. The remark captured the paradox of Greenspan’s influence: a single carefully chosen phrase could move markets around the world, yet his broader policy of accommodation often fueled the very exuberance he cautioned against.

A Complicated Legacy

Greenspan’s reputation, near-mythical at the height of his tenure, was significantly complicated by the events that followed his departure. Critics have pointed to his advocacy for financial sector deregulation and his sustained low-rate policies as contributing factors to the asset bubbles that culminated in the 2007-2009 global financial crisis. In 2008 testimony before lawmakers, Greenspan acknowledged he had mistakenly believed major banks would regulate themselves to protect their own shareholders — a candid admission of a flawed assumption at the heart of the crisis.

As one former senior Fed official observed, the near-deification Greenspan received before the crisis was never fully deserved, and the criticism he absorbed afterward was never fully deserved either. The truth of his legacy sits somewhere in between.

Why It Still Matters for Markets Today

Greenspan’s death arrives at a moment of renewed focus on Federal Reserve independence and communication. New Fed Chair Kevin Warsh, who presided over his first FOMC meeting just last week, has openly advocated for a less communicative, less predictable Fed — a notable departure from the era Greenspan defined, in which markets hung on the chairman’s every utterance. Warsh’s decision to slash the Fed’s post-meeting statement to 130 words and withhold his own dot-plot projection reflects a philosophy that stands in deliberate contrast to the Greenspan model.

For investors, Greenspan’s passing is a reminder of how profoundly central bank leadership shapes market conditions across cycles. The debates that defined his tenure — how much the Fed should intervene, how transparent it should be, how much faith to place in market self-correction — remain unresolved and are once again at the center of monetary policy under new leadership. The Maestro has died, but the questions he raised about the Fed’s proper role have never been more relevant.

Resolution Minerals Ltd (RLMLF) – Resolution Joins U.S. Defense Consortium

Posted on by [email protected]


Monday, June 22, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Strengthening its strategic position. Resolution Minerals has been admitted into the U.S. Defense Industrial Base Consortium (DIBC), a Department of Defense-supported network focused on strengthening critical supply chains and industrial capabilities. Membership provides the company with direct access to government agencies, industry partners, research institutions, and funding opportunities that support U.S. national security objectives.

Advancing critical minerals development. The membership aligns closely with Resolution’s strategy to develop domestic sources of antimony and tungsten, two minerals designated as critical to defense, aerospace, energy, and advanced manufacturing industries. The company has already submitted a funding application for its tungsten development plans and is evaluating additional opportunities to advance its antimony initiatives.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

MAIA Biotechnology (MAIA) – Stream Of Clinical Milestones Reported In June Shows Ateganosine Progress

Posted on by [email protected]


Monday, June 22, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Strong Progress Reported In Both Clinical Trials. MAIA currently has two clinical trials in progress. Both trials are testing the combination of ateganosine (aka THIO) and the checkpoint inhibitor cemiplimab (Libtayo, from Regeneron) as a third-line treatment for advanced non-small cell lung cancer (NSCLC). During June, MAIA opened two additional clinical sites for Phase 2 and reported strong enrollment progress in Phase 3.

Initial Phase 3 Enrollment Rate Has Been Strong. The Phase 3 THIO-104 trial began treating patients in early December. Within six months, the company opened 34 clinical sites and began treating 29 patients across 6 countries (select European countries, Turkey, Taiwan, and Georgia). THIO-104 has a target enrollment of 300 patients that will be randomized 1:1 to receive either the combination regimen or “investigator’s choice” of standard chemotherapies.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Graham (GHM) – Investor Day Highlights the Future

Posted on by [email protected]


Monday, June 22, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Investor Day. Graham management held an Investor Day last Thursday. Although the Company’s history extends back over 90 years, Graham is less than five years into the transformation of a reimagined company. Management went into depth on how the transformed Graham has expanded its capabilities, entered new markets, and positioned itself at the center of extraordinary growth opportunities.

New Markets. Graham has expanded its total addressable market over time, both organically and inorganically, through acquisitions such as Barber-Nichols in 2021, P3 Technologies in 2023, X-Dot in October 2025, and FlackTek in January 2026. The M&A pipeline remains robust, and we believe we could see ongoing transactions every 12-18 months to complement and expand the current product line and markets served.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Pump Prices Fall Under $4 Just in Time for Summer Travel Season

Posted on by [email protected]

The energy shock that defined the spring of 2026 is unwinding, and American consumers are feeling it at the pump just in time for summer. The national average price of regular gasoline fell to $3.99 per gallon Thursday, dropping below the $4 threshold for the first time in months and delivering meaningful relief to households that watched prices climb above $4.50 per gallon only a month ago at the height of the US-Iran conflict.

For the small and microcap companies that spent the spring absorbing elevated fuel costs with limited ability to pass them through, the decline is more than a consumer story. It is the early stage of a margin recovery that could reshape the second half of the year.

What’s Driving the Decline

The catalyst is diplomatic. Following President Trump’s announcement Sunday that Washington and Tehran had agreed to terms on a 60-day memorandum of understanding aimed at ending the three-month conflict and reopening the Strait of Hormuz to commercial traffic, crude oil prices have fallen sharply. Brent crude, the international benchmark, has dropped roughly 13% over the past five trading sessions to trade firmly below $80 per barrel for the first time since the early days of the war. US benchmark WTI crude has fallen even harder, shedding approximately 15% to trade below $75.

The scale of the recovery reflects the scale of the disruption. The shuttering of the Strait of Hormuz removed more than one billion barrels of oil from the global market over three months, creating one of the most severe supply squeezes in years. Gasoline and other crude derivatives, which carry embedded refining costs and are stored in smaller quantities, experienced even more dramatic price swings than crude itself — which is precisely why they are now falling quickly as the supply picture normalizes.

Industry analysts project the national average could head toward $3.70 per gallon in the near term as the Iran agreement takes hold and movement through the strait resumes, with diesel prices expected to fall below $5 per gallon shortly after.

The Small Cap Margin Story

For consumer-facing companies in the sub-$2 billion market cap range, the decline in fuel costs is a direct and measurable tailwind. Throughout the spring, regional trucking companies, last-mile delivery operators, food service businesses, and logistics providers absorbed surging diesel and gasoline costs that compressed already thin operating margins. Unlike large cap peers with hedging programs and pricing power, smaller operators had few options beyond eating the costs or risking demand destruction by raising prices.

That pressure is now reversing. Lower fuel costs flow almost immediately through to the operating expenses of transportation and logistics-dependent companies. Credit card data throughout the spring showed consumers spending an increasing share of their budgets on gasoline while cutting back elsewhere — a dynamic that squeezed discretionary small cap retailers and restaurant operators. As pump prices fall, that discretionary spending capacity returns, potentially benefiting the consumer-facing companies that had been most pressured.

The Caveats Worth Watching

The recovery is not without risk. Gasoline prices remain elevated above prewar levels, and a well-documented market phenomenon often described as “rockets and feathers” means pump prices tend to rise quickly when crude climbs but fall more slowly on the way back down. The timing of the Strait of Hormuz fully reopening remains uncertain, which means oil prices are unlikely to collapse dramatically as summer driving demand builds.

A more immediate threat comes from the weather. Tropical Storm Arthur is expected to impact the US Gulf Coast, home to the nation’s largest refinery complex. With US refineries already running at 97% of capacity according to federal data, any disruption from flooding could squeeze a system operating at its limit and temporarily reverse some of the relief now reaching consumers.

Barring significant storm damage or other disruptions, analysts project national average gasoline prices could fall below $3 per gallon by year-end, with diesel below $4. For the small cap companies that endured the spring squeeze, that would represent a full-circle recovery — and a meaningful tailwind heading into 2027.

Lands’ End (LE) – Multiple Paths to Value Creation

Posted on by [email protected]


Thursday, June 18, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Initiating coverage. The transformational WHP Global partnership unlocks hidden brand value by monetizing the Lands’ End intellectual property portfolio, eliminating significant balance-sheet risk, and providing access to WHP’s global licensing platform. In our view, the market is underappreciating the long-term earnings potential from licensing expansion and future profit-sharing opportunities.

A significantly strengthened balance sheet. Lands’ End fully repaid its $234 million term loan, reduced annual interest expense by more than $30 million, and provided substantial financial flexibility. The company now has the capacity to reinvest in growth initiatives while executing its recently authorized $100 million share repurchase program.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

First Phosphate Corp. (FRSPF) – First Phosphate Gains Strategic G7 Support for Critical Minerals Supply Chain Development

Posted on by [email protected]


Thursday, June 18, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

2026 G7 Summit in France. First Phosphate Corp. announced that it has secured international investment support and formalized offtake agreements under the Critical Minerals Resilience and Production Alliance at the 2026 G7 Summit in Evian, France. The developments underscore the company’s strategic importance in the effort by G7 nations and allied partners to develop secure and diversified critical mineral supply chains, particularly for lithium iron phosphate (LFP) battery production.

International Investment Support. First Phosphate has secured a letter of interest (LOI) from the Export and Investment Fund of Denmark (EIFO) for up to C$275 million in guarantees to support development of the Begin-Lamarche mine. The company has also received letters of interest from the Italian Export Credit Agency (SACE), from Italy’s National Promotional Institution, Cassa Depositi e Prestiti (CDP), and from the international growth partner for Italian companies (SIMEST). First Phosphate has also received support from the Italian engineering group MAIRE, with respect to First Phosphate’s phosphoric acid plant at Port Saguenay, to deploy Ballestra S.p.A (Italy) technology.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Intel Surges on Reported Apple Deal as One of the Year’s Most Dramatic Turnarounds Gains Steam

Posted on by [email protected]

Intel (Nasdaq: INTC) stock soared more than 11% Thursday after President Trump posted on Truth Social that Apple has agreed to work with the chipmaker to build its processors. The announcement followed an earlier Wall Street Journal report that the two companies had reached a preliminary agreement under which Intel would manufacture chips for the iPhone maker. Intel declined to comment on the report.

The move caps an extraordinary run for a company that was written off by much of Wall Street barely a year ago. Intel stock has now climbed more than 250% since the start of 2026 and roughly 500% over the past twelve months, making it one of the most dramatic corporate turnarounds in the technology sector.

Why the Apple Report Matters

The significance of a potential Apple partnership is as much symbolic as it is financial. Apple previously relied on Intel chips for its laptops and desktops before abandoning the company in favor of designing its own custom silicon — a high-profile departure that came to symbolize Intel’s competitive decline over the past decade. A renewed manufacturing relationship, even a modest one, would represent a meaningful reversal of that narrative.

Industry analysts have tempered expectations on the initial scope. Early commentary suggests any first agreement would likely involve lower-volume, less critical components rather than Apple’s flagship processors. Intel will need to prove its manufacturing reliability before earning more substantial business. But as analysts noted, the first step is always the hardest — and Intel appears to be taking it.

A Foundry Strategy Finally Paying Off

The Apple report does not exist in isolation. It is the latest in a series of developments validating Intel’s multi-year effort to build out its foundry business — the arm of the company that manufactures chips for third-party customers rather than just for Intel itself. Recent reports indicate Intel will build three million Tensor Processing Units for Google, and that Nvidia is exploring using Intel to fabricate some of its own processors. Earlier this week, Intel announced that its latest 18A-P processor node has entered initial production, a key step toward full-volume manufacturing.

The turnaround effort began under former CEO Pat Gelsinger and has continued under current CEO Lip-Bu Tan, who has focused on aggressive cost-cutting while driving the foundry arm to secure external manufacturing deals. That strategy is now benefiting from favorable industry dynamics. TSMC, the world’s largest chip manufacturer, has been unable to provide enough capacity for all of its customers, forcing fabless chip companies — those without their own manufacturing capabilities — to seek alternative production partners. Intel has emerged as one of the few viable options.

The AI Tailwind Beneath It All

Underpinning the entire Intel story is the AI build-out and a structural shift in chip demand. While graphics processing units remain central to AI data centers, central processing units have become increasingly important as AI firms lean into agentic applications — digital assistants capable of performing tasks on a user’s behalf. As AI agents begin running more operations across networks, they increasingly rely on CPUs to complete requests, a segment where Intel holds genuine strength.

For investors tracking the broader semiconductor ecosystem, Intel’s resurgence carries a wider signal. The capacity constraints pushing major customers toward Intel are the same constraints reshaping the entire chip supply chain. Smaller semiconductor companies, specialty foundry service providers, and advanced packaging firms operating in adjacent parts of that supply chain are positioned within the same demand environment driving Intel’s recovery. When the largest chip customers cannot get enough capacity from the dominant manufacturer, the effects ripple across the entire sector — and the smaller companies serving that demand are worth watching closely.

Intel was left for dead a year ago. A 500% move later, the turnaround is no longer a thesis. It is happening.

Vince Holding Corp. (VNCE) – Momentum Accelerates; Guidance Raised

Posted on by [email protected]


Wednesday, June 17, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Strong Q1 results and accelerating momentum. First-quarter revenue growth of $64.0 million, exceeding the high end of management’s guidance range, while adjusted EBITDA improved to a loss of $1.1 million from a loss of $3.0 million in the prior-year period. The quarter marked another step forward in the company’s transition from a turnaround story to a growth and earnings expansion story, with strength across both Direct-to-Consumer (DTC) and wholesale channels.

Growth driven by DTC and pricing. DTC sales rose 15.6%, wholesale sales increased 5.9%, and gross margin expanded despite tariff pressures, driven by higher pricing, lower discounting, and strong customer acquisition.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.